Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation by Dzeshka, M. S. & Lip, G. Y.
Author’s accepted manuscript 
Warfarin versus dabigatran 
etexilate: an assessment of efficacy 
and safety in patients with atrial 
fibrillation. 
Dzeshka MS, Lip GY 
Expert Opin Drug Saf. 2015 Jan; 14(1): 45-62. 
DOI: 10.1517/14740338.2015.973847 
  
Ре
по
зи
то
ри
й Г
рГ
М
У
1 
 
Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients 
with atrial fibrillation 
 
Abstract 
Introduction Oral anticoagulation is the mainstay for stroke and thromboembolic events 
prevention in patients with atrial fibrillation (AF). Given limitations of warfarin therapy non-
vitamin K oral anticoagulants have been developed, including direct thrombin inhibitors (i.e. 
dabigatran etexilate). Dabigatran etexilate has been tested thoroughly in terms of efficacy and 
safety in clinical trials and studies, involving ‘real world’ cohorts. In this review currently 
available evidence in patients with non-valvular AF is discussed. 
Areas covered  The pharmacology, efficacy and safety, and current aspects of use of 
dabigatran etexilate in patients with non-valvular AF are reviewed in comparative manner to 
warfarin both for chronic anticoagulation and in different clinical settings.  
Expert opinion Dabigatran etexilate appeared to have several pharmacokinetic and 
pharmacodynamic advantages over warfarin as well as a favourable efficacy and safety 
profile being at least non-inferior and often superior to warfarin in patients with non-valvular 
AF. The latter was shown in the clinical trials, meta-analyses and studies with ‘real world’ 
data. Currently ongoing trials will expand the body of evidence on warfarin and will aid 
decision-making in currently controversial areas. Important limitations of dabigatran etexilate 
include contraindications for its use in patients with prosthetic heart valves  and end-stage 
chronic kidney disease. 
Key words: dabigatran etexilate, warfarin, oral anticoagulation, atrial fibrillation, efficacy, 
safety.  
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1. Introduction 
 
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia which affects 
approximately 1-3% of general population (i.e. aged 20 years and older).1,2 AF is also 
increasing in prevalence and incidence, leading to a doubling of AF prevalence during next 
few decades.1 Given that AF is frequently asymptomatic, various new screening technologies 
allow detection of previously undiagnosed AF in about 1.5% of individuals age ≥65 years.3,4 
Stroke is known to be the most devastating and fearing complication of AF associated with 
prolonged disability, increased mortality and high health care costs.5 Moreover stroke is often 
the first manifestation of AF that can be diagnosed subsequently with long-term ECG 
monitoring.6 
 
Stroke risk is not homogenous and current guidelines7,8 focus on initial identification of low 
risk patients (i.e. those with lone AF and aged less than 65 years, essentially a CHA2DS2-
VASc score of 0 [males] or 1 [females]), who do not need any antithrombotic therapy. The 
subsequent step is that effective stroke prevention can be offered to patients with ≥1 
additional stroke risk factors in whom benefits of stroke and thromboembolic events 
prevention clearly outweigh risk of bleeding events.9,10 Current guidelines use the CHA2DS2-
VASc stroke risk assessment score whilst bleeding risk is assessed with the HAS-BLED 
score (Table 1).11,12 
 
Effective stroke prevention means oral anticoagulation (OAC). Warfarin, the main 
representative of the vitamin K antagonists, was the only available option of OAC for 
prevention of stroke and other thromboembolic complications in AF for many years until 
recently. Treatment with warfarin was found to reduce stroke rate both in primary and Ре
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secondary setting by 64 % (95% [confidence interval] 49-74) and all-cause mortality by 26 % 
(95% CI 3–43).12 However, a range of limitations, associated with the warfarin therapy, e.g. 
slow onset and offset of action, narrow therapeutic window, mandatory regular laboratory 
monitoring, multiple food and drug interactions, variability of response depending on genetic 
polymorphism and ethnicity, etc.) all triggered the development of alternative agents, the 
non-vitamin K OAC (NOAC) drugs as direct thrombin inhibitors (e.g. dabigatran etexilate) 
and factor Xa inhibitors (e.g. apixaban, rivaroxaban, edoxaban).14-16 
 
The current review is focused on the pharmacology, efficacy and safety of direct thrombin 
inhibitor dabigatran etexilate.  The latter has gained European Medicines Agency (EMA) 
approval for prevention of stroke and systemic embolism in patients with non-valvular AF 
and a risk factor for stroke; primary prevention of venous thromboembolic events (VTE) in 
patients undergoing elective total hip/knee replacement surgery; treatment of deep vein 
thrombosis (DVT) and pulmonary embolism; and the prevention of recurrent DVT and PE in 
adults.17   The United States Food and Drug Administration (FDA) has approved dabigatran 
etexilate to reduce the risk of stroke and systemic embolism in patients with non-valvular 
atrial fibrillation; for the treatment of DVT and PE in patients who have been treated with a 
parenteral anticoagulant for 5 to 10 days; and to reduce the risk of recurrence of DVT and PE 
in patients who have been previously treated.18  
 
Review of all available evidence on dabigatran etexilate in all approved conditions is far 
beyond the scope of one article. We would particularly focus on the efficacy and safety of 
dabigatran etexilate in different clinical situations in AF management as chronic 
anticoagulation in non-valvular AF, cardioversion and catheter ablation of AF, AF in patients 
with coronary heart disease, chronic kidney disease, obesity, etc. Ре
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2. Pharmacology of dabigatran and warfarin 
 
Treatment with warfarin results in synthesis of vitamin K dependant coagulation factors (i.e. 
II, VII, IX, X, Figure 1) with decreased coagulation activity because of reduced number of 
carboxylated residues of glutamic acid. Carboxylated residues serve as calcium-binding 
domains and are essential to reach positive charge with calcium ions. Positively charged 
coagulation factors are then attracted to injured vessel wall with negative charge and cause 
downstream activation of coagulation cascade.19 Balancing the carboxylated and 
decarboxylated calcium-binding domains and, hence, degree of anticoagulation depends on 
extent of vitamin K epoxide reductase complex subunit 1 (VKORC1) inhibition with 
warfarin.19 Presence of different genetic variants of the VKORC1 as well as of cytochrome 
P450-2C9 [CYP2C9] and few other genes in individual determines extent and wide 
variability of anticoagulation effect of warfarin.19 
 
On the contrary, direct thrombin inhibitors (e.g., dabigatran) bind to active catalytic site of 
thrombin (factor IIa, serine protease) in competitive and reversible manner and block the final 
stage of coagulation cascade, i.e. synthesis of fibrin from fibrinogen and its stabilization 
(Figure 1).20-22 Dabigatran is capable of inhibiting both free thrombin and fibrin-bound 
thrombin. Because thrombin realizes multiple effects in haemostatic system, e.g. activation of 
coagulation factors V, VIII, XI and XIII; inhibition of fibrinolysis; platelet activation; 
inflammatory changes, etc., dabigatran interferes with these reactions as well.20-22 
 
The drug was developed as non-active pro-drug dabigatran etexilate (drug substance is the 
mesilate salt of dabigatran etexilate) that is converted into dabigatran in vivo (in the gut Ре
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mucosa, liver and plasma) via non-specific ubiquitous esterases, specifically 
carboxylesterase-1.  
 
The oral bioavailability of dabigatran in capsules is approximately 6.5% (ranging 3 to 7 %). It 
showed moderate to high intersubject variability of 31.4% and 53.5% for the area under the 
plasma concentration–time curve at steady state in healthy volunteers.23 Removing the 
hydroxypropyl methylcellulose shell that encapsulates dabigatran etexilate and helps to 
stabilize the drug may signiﬁcantly increase (by 75 %) dabigatran bioavailability. Food intake 
does not affect bioavailability of dabigatran.   Formulation of dabigatran etexilate with 
tartaric acid allows to reduce the variability of its absorption, which is originally dependent 
on gastrointestinal tract acidity. For example, co-administration with pantoprazole decreases 
the bioavailability of dabigatran with the peak plasma concentration at steady state of 
approximately 28% lower with the proton pump inhibitor than without it.24   Renal excretion 
is the dominant elimination pathway (up to 80%) for dabigatran applies limitations for 
patients with reduced glomerular filtration rate.16,25-27 Pharmacological characteristics of 
dabigatran versus warfarin are summarized in table 2. 
 
Thus, dabigatran etexilate in comparison to warfarin has range of advantages: fixed dose and 
no need for frequent laboratory control, more rapid onset and shorter offset of action, fewer 
drug and no food interactions. 
 
3. Efficacy and safety of dabigatran in atrial fibrillation 
 
3.1 Chronic anticoagulation in non-valvular AF Ре
по
зи
то
ри
й Г
рГ
М
У
6 
 
The RE-LY (Randomized Evaluation of Long-term anticoagulation therapy) trial was open-
label between dose-adjusted warfarin (international normalized ratio [INR] 2.0-3.0) and 
dabigatran arms but double-blind between two dabigatran doses, i.e., 150 and 110 mg twice a 
day (Table 3).28,29 
The efficacy analysis showed non-inferiority of dabigatran etexilate 110 mg bid (1.54 
%/year) and superiority of dabigatran etexilate 150 mg bid (1.11 %/year) to warfarin (1.71 
%/year) for prevention of stroke and systemic embolism.28,29 Whilst the rate of major 
bleeding did not differ between warfarin (3.57 %/year) and dabigatran etexilate 150 mg bid 
(3.32 %/year) and was lower in dabigatran etexilate 110 mg bid arm (2.87%/year), both 
dosing regimens were associated with reduced risk of intracranial haemorrhage (ICH): 0.23 
and 0.30 %/year in dabigatran etexilate arms, 110 mg and 150 mg bid respectively versus 
0.74 %/year in warfarin arm.28,29 Noteworthy, results on primary efficacy and safety outcome 
appeared to be consistent across different stroke risk strata (based on the CHADS2 score).
30  
However, there was an increased risk of gastrointestinal bleeding but with high dose regimen 
only (1.51 versus 1.02 %/year).28 
 
A non-significant increase in rate of myocardial infarction (MI) was observed in both 
dabigatran arms. But cardio-vascular and all-cause mortality did not differ between warfarin 
and the dabigatran etexilate arms, and dabigatran etexilate 150 mg bid was even associated 
with a lower risk of cardio-vascular mortality.28,29  
 
Both doses of dabigatran etexilate remained non-inferior to warfarin in patients with previous 
history of stroke or transient ischaemic attack.31 In this subset of patients, treatment with 
dabigatran etexilate resulted in reduction of haemorrhagic stroke when compared to warfarin 
(relative risk [RR] 0.27, 95% CI 0.10–0.72 for dabigatran etexilate 150 mg bid; RR 0.11, Ре
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95% CI 0.03–0.47 for dabigatran etexilate 110 mg bid) and ICH (RR 0.20, 95% CI 0.08–0.47 
for dabigatran etexilate 150 mg bid; RR 0.41, 95% CI 0.21–0.79 for dabigatran etexilate 110 
mg bid).31 Low dose of dabigatran was also associated with a reduced rate of death from 
vascular causes (RR 0.63, 95% CI 0.43–0.92) and death from any cause (RR 0.70, 95 CI% 
0.53–0.94).31 
 
In a modelling analysis, when hazard ratios (HR) from the RE-LY trial were applied to the 
high-risk (CHA₂DS₂-VASc score ≥2) population from the EuroHeart Survey on AF 34 
strokes could be prevented with dabigatran etexilate 150 mg bid, and 16 strokes and 6 major 
bleeds could be avoided with dabigatran etexilate 110 mg bid in comparison to therapy in the 
study, which were warfarin, aspirin or nothing.32 For the whole European population this 
would mean prevention of an additional 43 235 major cardiovascular events and deaths each 
year among patients with a CHA2DS2-VASc score ≥2 with the use of dabigatran etexilate 150 
mg bid and 27 272 with the use of dabigatran etexilate 110 mg bid.32 Another post-hoc 
simulation of dabigatran etexilate use based on the RE-LY trial dataset but with current 
European indications and dosing (Table 2) confirmed higher net clinical benefit of dabigatran 
etexilate administration in comparison to warfarin.33  
 
Approximately half of patients under dabigatran etexilate treatment from the RE-LY trial 
were enrolled to the Long-term Multicenter Extension of Dabigatran Treatment in Patients 
with Atrial Fibrillation (RELY-ABLE) in which consistent with the RE-LY data were 
obtained as for the rates of major ischemic, haemorrhagic, and fatal outcomes. The only 
difference between low and high doses of dabigatran etexilate was the rate of major bleeding, 
which was higher with the 150 mg bid regime (HR 1.26; 95% CI 1.04-1.53).34 
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Given the results from the pivotal trial on dabigatran etexilate it was quite unexpected to 
initially get unusually high number of reports (via FDA Adverse Event Reporting System) of 
serious and fatal bleeding events associated with the dabigatran etexilate administration. The 
rate of bleeding events appeared to be even higher than amongst patients taking warfarin.35 
One explanation for this was the so-called ‘Weber effect’ where newly introduced drugs had 
an initial excess high rate of submission of adverse reports on serious bleeding driven by 
novelty and increased attention to the ‘new’ dabigatran etexilate versus the ‘old’ drug 
warfarin.36 
 
In subsequent analysis undertaken by FDA on the actual rates of gastrointestinal and ICH in 
anticoagulation-naïve patients with AF starting dabigatran etexilate or warfarin confirmed 
favourable safety profile of dabigatran.37 Data were collected from FDA's Mini-Sentinel 
database, pilot project of surveillance system the Sentinel Initiative, that monitors the safety 
of FDA-regulated medical products and included more than ten thousand records.37 The 
incidence rate per 100 000 days at risk appeared to be 2.1-3.0 and 1.6-2.2 times higher in new 
warfarin users for intracranial and gastrointestinal haemorrhage respectively.37 Because data 
were collected from insurance claims and administrative data no adjustment was performed 
for confounding bleeding risk factors and medical records were not reviewed for actual 
presence of AF and bleeding events in involved patients.37 
 
Finally, the most recent analysis carried out by FDA amongst Medicare beneficiaries aged 65 
years or more (>134 000 patients included and 37 500 person-years of follow-up) showed 
lower risk of ischaemic stroke (HR 0.80, 95% CI 0.67-0.96); ICH (HR 0.34, 95% CI 0.26-
0.46) and mortality (HR 0.86, 95%CI 0.77-0.96) in AF patients taking either dabigatran 
etexilate 150 mg bid or 75 mg bid if dose reduction was necessary in comparison to those Ре
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taking warfarin.38 There was higher rate of major gastrointestinal bleeding (HR 1.28, 95% CI 
1.14-1.44) in patients treated with dabigatran, but no difference was observed with respect to 
risk of MI (HR 0.92, 95% CI 0.78-1.08).38 Thus, apart from data on MI rate, results from 
Medicare database appeared to be consistent with those from the RE-LY trial.  
 
Additional dabigatran etexilate safety and efficacy were obtained in the ‘real world’ Danish 
nationwide cohort study (Table 3).39 The major difference from the RE-LY trial was even 
better safety profile of dabigatran etexilate, for example lower rate of gastrointestinal 
bleeding in low dose and the same rate in high dose dabigatran etexilate as well as lower risk 
of MI with both doses, which were attributed in part to the generally lower risk population 
from everyday clinical practice.39 Interestingly, an earlier modeling analysis on patients from 
the Danish National Patient Registry also showed a positive net clinical benefit of dabigatran 
etexilate over warfarin starting from the CHA2DS2-VASc score of 1 regardless of risk of 
bleeding with the greatest benefit expected in patients with both high risk of stroke and 
bleeding.40  
 
3.2 Impact of dabigatran exposure on its efficacy and safety  
Safety and efficacy of dabigatran may be correlated to its plasma levels. Polymorphism of 
two genes, CES1 encoding carboxylesterase-1, and ABCB1, encoding polymorphic drug 
efflux transporter permeability glycoprotein (P-gp) have been shown to have impact on 
dabigatran concentrations.41  In a genome-wide association study in the RE-LY participants 
the CES1 single-nucleotide polymorphism rs2244613 was found to be associated with both 
trough (15% decrease per minor allele) and peak (12% decrease per minor allele) plasma 
concentrations of dabigatran whilst for rs8192935 association with peak concentration (12% 
decrease per minor allele) was revealed.41  Ре
по
зи
то
ри
й Г
рГ
М
У
10 
 
There was significantly lower risk of any bleeding in minor allele carriers (HR 0.72, 95% CI, 
0.58–0.90) but only non-significant trend towards lower risk of major bleeding. No 
association was observed with ischemic events as well. For the CES1 single-nucleotide 
polymorphism rs8192935 as well as ABCB1 single-nucleotide polymorphism rs4148738 
(12% increase in dabigatran peak concentration per minor allele) no associations were 
observed with any adverse clinical events.41 Importantly, CES1 rs2244613 minor allele was 
detected in 32.8% of patients in the RE-LY trial, however there were only 3.4% of patients, 
who were homozygous for this allele.41  
 
Overall in the RE-LY population 5.2-fold (28.2 to 155 ng/mL) and 5.5-fold (39.8 to 215 
ng/mL) variability of dabigatran concentration between 10th and 90th percentiles was 
observed for 110 mg bid and 150 mg bid regimes respectively.42 Thus, a proportion of 
patients appeared to have very low (and, hence, decreased stroke protection) or very high 
(and, hence, increased bleeding risk) plasma levels of dabigatran. Concentration-dependent 
increased risk of bleeding events was observed: patients with major bleeds had dabigatran 
concentrations (geometric mean, 10th-90th percentiles) of 113 (46.7-269) ng/mL versus 72.8 
(30.7-175) ng/mL in patients without any bleeds.42 On the contrary, the risk of stroke and 
systemic embolism was less dependent on dabigatran plasma levels: 76.6 (26.4-185) ng/mL 
versus 76.5 (32.1-186) ng/mL in patients with and without occurrence of events 
respectively.42  
 
These data raised concerns about necessity of laboratory control of dabigatran concentration 
and appropriate dose adjustment instead of fixed dose regime in order to improve further 
patients outcomes, particularly, to reduce risk of bleeding complications.43-45 An algorithm 
for dabigatran etexilate dose adjustment has even been proposed, that includes assessment of Ре
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dabigatran trough concentration (Ctrough) after one week treatment with dabigatran etexilate 
150 mg bid, followed by dose reduction to 75 mg bid if Ctrough ≥140 ng/mL; 110 mg bid if 
Ctrough ≥90 and <140 ng/mL; or continuation of the 150 bid regime if Ctrough <90 ng/mL.
43  Of 
note, EMA published therapeutic ranges for dabigatran of 48 ng/mL (concentration below 
which partial loss of efficacy is very likely) to 200 ng/mL (concentration above which risk of 
bleeding is increased),46 which is very close to 10th-90th percentile range obtained with the 
150 mg bid regime in the RE-LY trial.42  
 
Dose adjustment for dabigatran etexilate perhaps is reasonable in selected group of patients at 
higher risk (e.g., elderly and/or those with renal dysfunction). However, at a population level 
such an approach will eventually meet many obstacles as absence of routinely available 
assays for measurement of dabigatran concentration, and a considerable decrease of 
practicality of anticoagulation management, as well as a reduction of adherence to more 
complex treatment schemes, higher probability of mistakes, etc.  
 
Also, the variability of dabigatran concentration should be perceived against the trial results, 
i.e. at least non-inferiority of dabigatran etexilate fixed dose approach to well-adjusted 
warfarin. Taken together these data indicate a wide therapeutic window of dabigatran 
etexilate.  Moreover modelling analyses, performed by Boehringer Ingelheim, failed to 
predict reliably actual patients outcomes when dose adjustment strategy was applied, 
supporting fixed dose regime.47   
 
Thus, future prospective trials are warranted to answer whether assay-guided dosing or 
genotyping will lead to improvement of dabigatran etexilate therapy and optimization of the 
balance between efficacy and safety. Ре
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3.3 Cardioversion of atrial fibrillation 
Cardioversion of AF to sinus rhythm is associated with an increased risk of thromboembolic 
complications, therefore in patients with AF of ≥48 h or unknown duration OAC is required 
at least 3 weeks before and a minimum of 4 weeks after cardioversion (whether direct current 
or pharmacological) although OAC should be continued subsequently based on stroke risk 
according to CHA2DS2-VASc score.
7,8 
 
One retrospective analysis included patients who underwent cardioversion within the RE-LY 
trial.48 Total of 1 983 cardioversions were performed in 1 270 patients, vast majority of which 
were direct current cardioversions. Numbers of patients with either left atrial (LA) thrombus 
(1.8% and 1.2% in low and high dose of dabigatran, respectively, versus 1.1% in warfarin 
arm) or left atrial spontaneous echo contrast (21.2% and 27.2% in low and high dose of 
dabigatran etexilate, respectively, versus 31.8 % in warfarin arm) on transoesophageal 
echocardiography (TOE) did not differ between three treatment groups. Analysis revealed the 
following rate of stroke and thromboembolic events: 0.48% and 0.46% for treatment with 
dabigatran etexilate (similar for both doses) and warfarin, respectively.48 Rates of major 
bleeding also did not differ between groups: 2.66% in high dose dabigatran etexilate, 0.48% 
in low dose dabigatran etexilate, and 0.46% in warfarin.48 Also, no complications related to 
cardioversion and no echocardiographic evidence of LA thrombus at a background of 
anticoagulation with dabigatran etexilate were observed in small retrospective study of 
Yadlapati et al.49  
 
Transoesphageal echocardiography (TOE) is probably the most sensitive and specific 
technique to detect LA or LA appendage (LAA) thrombi as a potential source of systemic Ре
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embolism in AF. TOE guided cardioversion is an alternative to 3 weeks of anticoagulation 
prior to cardioversion.7,8,50-52 For patients undergoing TOE-guided cardioversion who have no 
identifiable thrombus, cardioversion is recommended immediately after anticoagulation with 
heparin. If thrombus is identified, appropriate oral anticoagulation is required for at least 3 
weeks, followed by a repeat TOE to ensure thrombus resolution. If thrombus resolution is 
evident on repeat TOE, cardioversion can be performed. If thrombus remains on repeat TOE, 
cardioversion is contraindicated, and alternative strategy (e.g. rate control) may be 
considered. LA/LAA thrombus should also be excluded before catheter ablation of AF.7,8 
Importantly, the absence of LA/LAA thrombus on TOE gives an opportunity to shorten time 
cardioversion but does not preclude the need for anticoagulation during (with heparin) and 
after cardioversion (with OAC). Thus, anticoagulation during pericardioversion period with 
dabigatran etexilate is a reasonable option, particularly given a more predictable 
anticoagulation effect.  
 
No laboratory assays are available for routine estimation of anticoagulation intensity with 
dabigatran etexilate and those alternative (e.g., diluted thrombin time, or ecarin clotting time) 
have important limitations as availability, sensitivity, variability and lack of validation.53-56 
Thrombin time (TT) and activated partial thromboplastin time (aPTT) can be used to ensure 
to some extent that patient is sufficiently anticoagulated. TT was found to be sensitive to the 
presence of dabigatran with a level of 60 ng/mL resulting in a marked prolongation of TT (> 
300 s).55 The aPTT was correlated with the dabigatran level but showed variability of the 
results depending on used aPTT reagents. It was also less responsive to high dabigatran 
concentration (plato with supratherapeutic levels of dabigatran).55 Moreover, both parameters 
are often normal despite the therapeutic dabigatran plasma levels.56  Thus, it is also of 
paramount importance to emphasise patient compliance to treatment before cardioversion. Ре
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3.4 Catheter ablation of atrial fibrillation 
Radiofrequency catheter ablation for AF is increasingly used procedure in patients with 
symptomatic recurrent AF paroxysms, which are poorly tolerated or refractory to 
antiarrhythmic medications.7,8,57 
 
In line with pre-existed risk of thromboembolic events in patients (e.g., those incorporated 
into the CHA2DS2-VASc score) there are additional factors which contribute to development 
of thromboembolic complications during the ablation procedure and post-procedural period, 
for example presence of foreign bodies in the circulation and areas of stasis produced by 
catheters, sheaths, and guidewires; blood proteins denaturation, endothelium damage, atrial 
stunning caused by tissue heating with radiofrequency energy, etc.58 
 
Historically, patient underwent bridging with heparin before and following the ablation 
procedure. Given the increased number of bleeding complications, recommendations on 
periablation anticoagulation in AF changed in favour of uninterrupted treatment with 
warfarin that was associated with reduction of thromboembolic events at no cost of increased 
bleeding.59,60 Importantly, despite both paroxysmal and non-paroxysmal AF confers 
increased risk of stroke and systemic embolism, in the periablation setting non-paroxysmal 
AF along with warfarin discontinuation and the CHADS2 score were found to be an 
independent predictor of thromboembolic complications after catheter ablation of AF.60 
 
As in cardioversion for AF at least three weeks of systemic anticoagulation at a therapeutic 
level is required in case of AF duration of 48 hours or longer (or unknown) prior to ablation Ре
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procedure, but anticoagulation during minimum of two months is required following the 
ablation.57 
 
Patients with planned ablation were excluded from the RE-LY trial.28 Uninterrupted 
treatment with dabigatran etexilate (with only one dose of dabigatran on the morning of the 
procedure being held and resumed within 3 hours after haemostasis) resulted in a 
significantly higher rate of bleeding or thromboembolic complications (odds ratio [OR] 2.76, 
95% CI 1.22-6.25), which was driven by bleeding complications mostly (major bleeding rate 
6% versus 1%, total bleeding rate 14% versus 6%, in dabigatran and warfarin groups, 
respectively).61 On the contrary, in one study with the same approach (heparin was used after 
ablation in few cases depending on status of femoral puncture sites) no bleeding or 
thromboembolic complications were observed during periprocedural period and up to one 
year follow-up.62 
 
Plenty of studies, which tested approach with interrupted dabigatran etexilate, typically 
withheld 12-24 hours pre-procedure and resumed 3-4 hours after vascular haemostasis was 
achieved (or alternatively heparin was given after procedure and dabigatran etexilate was 
started the day after the intervention), yielded a comparable safety profile for dabigatran 
etexilate and warfarin.63-67 
 
In the absence of randomised controlled trials the best available evidence is that obtained 
from meta-analyses of smaller studies on safety and efficacy of dabigatran etexilate versus 
warfarin in patients undergoing catheter ablation (Table 4).68-73 The majority of currently 
published meta-analyses provides reasonable support towards the safety and efficacy of 
dabigatran in the setting of ablation. Meta-analyses of Sardar et al included many studies with Ре
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more than 2 doses held before ablation, i.e. longer time of anticoagulation state that might be 
possible explanation for higher risk of stroke and TIA in comparison to warfarin.71 
 
The RE-CIRCUIT trial (Randomized Evaluation of dabigatran etexilate Compared to 
warfarIn in pulmonaRy vein ablation: assessment of different peri-proCedUral 
antIcoagulation sTrategies) has been designed to prospectively evaluate uninterrupted 
treatment with dabigatran etexilate compared to warfarin, in patients with paroxysmal or 
persistent non-valvular AF who are scheduled to undergo a first ablation procedure, and will 
give a final answer on safety and efficacy of dabigatran in catheter ablation of AF.74  
 
3.5 Acute and chronic coronary heart disease in association with atrial fibrillation 
A substantial proportion of AF patients are those with coronary heart disease.75 and need to 
undergo percutaneous intervention (PCI), often with stent implantation, these patients require 
therefore combination of OAC and anti-platelet agents (triple therapy) to cover both 
activation of coagulation cascade (predominant pathway in AF) and platelet activation and 
aggregation (predominant pathway in coronary heart disease).76,77  
 
In the RE-LY trial 32.0% of patients received combination of OAC and aspirin alone, 1.9% - 
OAC and clopidogrel alone and 4.5% - OAC and both aspirin and clopidogrel.78 Not 
surprisingly, concomitant use of a single antiplatelet agent brought increased risk of major 
bleeding (HR 1.60, 95% CI, 1.42–1.82), which was even higher with dual antiplatelet therapy 
(HR 2.31, 95% CI 1.79–2.98).78 However, adding antiplatelet therapy did not affect 
advantages of dabigatran etexilate over warfarin. Low dose dabigatran etexilate remained 
non-inferior to warfarin with respect to stroke and systemic embolism and superior with 
respect to major bleeding and ICH.78 In high dose dabigatran etexilate adding antiplatelet Ре
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therapy was associated with partially attenuated effect on stroke and systemic embolism 
prevention (non-inferior to warfarin) in comparison to subgroup with no antiplatelet therapy 
(superior to warfarin) but the same rate of major bleeding and lower rate of ICH were 
observed with dabigatran etexilate irrespectively of aspirin and/or clopidogrel used 
concomitantly.78 
 
Another important issue of dabigatran use in patients with coronary heart disease is a non-
significant trend towards increased rate of MI when compared with warfarin treatment, 
raising concerns that dabigatran etexilate may not provide appropriate protection against MI 
in patients with AF and coronary heart disease.79 Whilst there was non-significant numerical 
increase observed in the RE-LY trial28,29, several meta-analyses (which included trials on 
dabigatran etexilate in AF, acute coronary syndrome, PE and DVT) following it found 
increased risk of MI to be significant.80,81  Overall similar results (more MIs with dabigatran 
etexilate) were obtained when any single study (including the RE-LY trial) was excluded 
from the analysis.80,81  There was no increase in MI rate observed in trials with the factor Xa 
inhibitors, rivaroxaban and apixaban – however, numerically more MIs was seen with low-
dose edoxaban compared to warfarin in the ENGAGE-AF trial.82-84 
 
Larsen et al, who reported overall lower risk of MI in the ‘real world’ AF population in 
Denmark39, in subgroup analysis amongst anticoagulation-naïve ‘starters’ of dabigatran 
etexilate or warfarin, and VKA-experienced ‘continuers’ of warfarin or ‘switchers’ from 
warfarin to dabigatran etexilate distinguished the latter to be the only group, that was at 
increased risk of MI, and only during early period after switching (within 2 months): HR 
3.01, 95% CI 1.48-6.10 for 110 mg bid dosage; HR 2.97, 95% CI 1.31-6.73 for 150 mg bid Ре
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dosage.85 Otherwise, MI rate was broadly the same with trend to lower risk in dabigatran 
starters and higher rate in warfarin to dabigatran switchers (irrespectively of time).85 
 
One widely accepted explanation of higher rate of MI at a background of dabigatran comes 
from its pharmacology. Whilst warfarin acts by suppressing the synthesis of several 
coagulation factors (II, VII, IX, X) dabigatran inhibits activated factor II only. Hence, with 
the rupture of an atherosclerotic plaque, a patient receiving warfarin would have a low factor 
II level and would generate fewer factor IIa. On the contrast, a patient receiving dabigatran 
etexilate would have normal levels of factor II and inhibitory capacity of dabigatran etexilate 
dose sufficient for chronic systemic anticoagulation is probably insufficient to prevent 
coronary thrombosis as a result of locally increased factor II concentration in acute setting.86 
Also, if to compare impact of direct thrombin inhibitors and factor Xa inhibitors on 
coagulation, certain differences were seen with respect to thrombin generation as assessed 
with calibrated automated thrombogram. Various parameters can be measured with this 
assay, which allow characterising of the initiation, propagation and decay phase of thrombin 
generation.87,88 Direct thrombin inhibitors were found to be more active in delaying the 
initiation phase of thrombin generation (lag time) whilst factor Xa inhibitors exerted a greater 
effect on propagation phase (time to peak and endogenous thrombin potential) that eventually 
might also affect risk of MI development.87,88 
 
Nonetheless, according to current evidence overall magnitude of reduction in stroke, ICH and 
cardiovascular mortality seems to overweigh moderate increase of MI risk. The RE-DUAL 
PCI trial has been designed to investigate the efficacy and safety of dabigatran etexilate in 
patients with non-valvular AF who have undergone PCI with stenting.89 
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3.6 Chronic kidney disease in association with atrial fibrillation 
On the one hand chronic kidney disease is associated with an increased risk of stroke or 
systemic thromboembolism and bleeding among patients with AF90-93; on the other, up to 
80% of dabigatran are excreted via kidneys. In the RE-LY trial dabigatran etexilate was 
contraindicated in patients with creatinine clearance below 30 mL/min. The latter was further 
reflected amongst range of contraindications for dabigatran etexilate in the EU label. The 75 
mg bid dose was approved by the FDA in the US for patients with CrCl 15-30 mL/min based 
on pharmacokinetic modeling and simulation.94 A clinical trial to evaluate safety and efficacy 
of the latter regime has been designed thereafter.95 In patients with CrCl below 15 mL/min 
only vitamin K antagonists can be used. 
 
Thus, OAC use with dabigatran etexilate in AF at a background of chronic kidney disease is 
largely challenging.96 In the ancillary analysis of the RE-LY trial on the efficacy and safety of 
dabigatran etexilate in relation to baseline renal function, rates of stroke or systemic 
embolism, major bleeding, and all-cause mortality increased with the decreasing glomerular 
filtration rate.97 In general results for both doses of dabigatran etexilate were found to be 
consistent with the whole RE-LY trial irrespective of renal function, i.e. 110 mg bid dose was 
non-inferior to warfarin in terms of stroke and systemic embolism and superior in terms of 
ICH as well as 150 mg bid dosage was superior to warfarin in both cases.97 Major bleeding 
was best prevented with both dosages of dabigatran in comparison to warfarin in patients 
with CrCl ≥80 mL/min, however with the progression of kidney dysfunction dabigatran 
showed only safety comparable to warfarin.97 
 
Interestingly, anticoagulation with either dose of dabigatran etexilate in AF patients appeared 
to have a favourable effect on kidney function deterioration over time in comparison to Ре
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warfarin. The precise mechanism is not known, however vascular calcification with warfarin 
is one possible explanation.98  
 
Importantly, low protein binding and high water solubility of dabigatran make it appropriate 
for removal with haemodialysis (for example in case of acute kidney injury, overdosing or 
any other emergent setting). Dabigatran plasma levels can be reduced approximately by half 
during 4 hours haemodialysis, which is also associated with proportional reduction of its 
anticoagulant activity.99-101 
 
3.7 Anticoagulation with dabigatran etexilate in patients with obesity 
Obesity is characterised with continuously increasing prevalence. Over half of the adult 
population in the world is expected to be overweight or to suffer from obesity by 2030.102  It 
is also considered to be one of risk factors of incident AF.103,104  
 
Stroke prevention in this group of patients is challenging because increased body weight 
affects pharmacokinetic properties of oral anticoagulants. For example, obesity was found to 
result in functional and structural kidney changes which lead to increased plasma flow and 
glomerular hyperfiltration.105 Glomerular hyperfiltration apparently will result into increased 
drug clearance (for drugs with predominantly renal clearance) and, hence, lower plasma 
concentration of drug with the same dose compared to normally weighted individuals. Of 
note, relation between body weight and drug clearance is not linear. The latter depends more 
from lean body weight rather than from total one.106 Increased body weight also has impact 
on distribution volume. 
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From this point of view fixed dose regime of anticoagulation with dabigatran etexilate could 
provide insufficient stroke protection in obese patients with AF. Amongst patients involved 
in the RE-LY trial there was inverse relationship between trough plasma concentration of 
dabigatran and body weight.107 Nonetheless this did not translate into poorer outcomes in 
terms of stroke or systemic embolism with dabigatran etexilate in patients weighed over 100 
kg (approximately 17% of patients in the RE-LY trial) in comparison to those with weight of 
<50 kg or 50 to 99 kg. Also, no difference with respect to efficacy and safety of dabigatran 
etexilate was observed in patients with body mass index (BMI) >25 kg/m2 and overall 
population in the pooled analysis of venous thromboembolism prevention trials.108  The 
negligible impact of increased body weight on area under the plasma concentration–time 
curve at steady state was also shown in a  pharmacokinetic study with dabigatran etexilate in 
patients from the RE-LY cohort. Amongst tested parameters only kidney function was found 
to affect dabigatran plasma level in such a degree, which eventually might require dose 
adjustment.94  Thus, dabigatran etexilate can be considered effective in obese patients. Given 
relatively scarce evidence, degree of obesity should be considered because effect of body 
weight in morbidly obese patients (i.e. BMI >40 kg/m2) on dabigatran etexilate 
pharmacokinetics may potentially be more profound.  
 
3.8 Periprocedural management of dabigatran etexilate therapy 
The need for surgical intervention or invasive procedure amongst patients with AF under 
OAC is quite common. Balancing risk of stroke and systemic embolism on the one hand and 
risk of major bleeding on the other in this case is even more complicated. The risk of major 
periprocedural bleeding with OAC depends on the type of procedure. Minimal procedures are 
those with little tissue trauma (superficial skin and oral mucosal surgery, including skin 
biopsies, wound revisions, non-extraction dental treatment). Minor procedures were Ре
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procedures with little tissue trauma, but relevant bleeding risk: transluminal interventions, 
pacemaker-related surgery, pleural and peritoneal puncture, eye surgery, endoscopy, 
laparoscopy, organ biopsies, dental extraction, etc. Major procedures include open pelvic, 
abdominal and thoracic surgery, brain, vascular, orthopaedic and trauma surgery, i.e. surgery 
associated with significant tissue trauma and high bleeding risk.109 
 
As dabigatran has faster onset and offset of action, more predictable pharmacodynamics and 
pharmacokinetic properties and less drug interactions in comparison to warfarin, use of 
dabigatran etexilate in periprocedural setting seems to be advantageous. However, the 
absence of antidote and routine laboratory test applies limitations.  
 
Whilst warfarin requires INR adjustment and/or temporal interruption and bridging with 
heparin (particularly in patients with high risk of thromboembolic events and undergoing 
high bleeding risk procedures)110, dabigatran etexilate probably does not. Minimal procedures 
can be performed at trough concentration (but not at the peak one which is at 2 hours after 
ingestion) with skipping one dose of dabigatran etexilate and restarting 6 hours after 
procedure.16 Minor procedures require discontinuation of dabigatran for at least 24 hours  
before the elective procedure in patients with CrCl>80 mL/min, 36 hours – in patients with 
CrCl 50-80 mL/min, and 48 hours - in patients with CrCl 30-50 mL/min.16 In case of major 
procedures above mentioned time intervals should be doubled. Resuming of full dose 
anticoagulation is possible within the first 48–72 hours.16  
 
In case of emergent surgery, anticoagulant intensity of warfarin can be easily measured by 
the INR, and reversed if necessary with vitamin K, fresh frozen plasma, or prothrombin 
complex concentrate.111 In patients anticoagulated with dabigatran etexilate it is Ре
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recommended to postpone surgery as long as possible.16 Also dabigatran plasma 
concentration can be taken into account if appropriate facilities are available. EMA and 
Working Group on Perioperative Haemostasis (GIHP) suggested 48 ng/ml and 30 ng/ml, 
respectively as cut-off levels, below which surgery might be safely performed.112 
 
If bleeding developed, in line with local haemostatic measures reversal agents can be used, 
which currently include activated and non-activated prothrombin complex concentrate and 
recombinant factor VIIa, but they should be used with caution as associated with high 
prothrombotic risk.112-114  
 
Idarucizumab, a fully humanized antibody fragment (Fab), which was developed as a specific 
antidote for dabigatran will be evaluated in patients with uncontrolled bleeding or requiring 
emergency surgery or procedures.115 
 
Approximately 25% of AF patients in the RE-LY study underwent at least one invasive 
procedure during follow-up, most common were insertion of implantable device, dental 
procedures, diagnostic procedures, cataract removal, colonoscopy and joint replacement.116 
Importantly, dabigatran etexilate and warfarin were associated with similar rates of 
periprocedural bleeding, both in elective and urgent settings.116 Noteworthy, treatment with 
dabigatran etexilate was associated with a shorter interruption of oral anticoagulation, i.e. 
shorter time at increased risk of stroke and thromboembolic events.116 
 
3.9 Prosthetic heart valves and dabigatran etexilate 
The RE-ALIGN trial (The Randomized, phase II study to evaluate the safety and 
pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement) Ре
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enrolled patients who underwent aortic- or mitral-valve replacement and was terminated 
prematurely due to excess of thromboembolic and bleeding events among patients in the 
dabigatran arm compared with warfarin. Mechanical prosthetic heart valves are therefore a 
contraindication for the use of dabigatran.117 
 
4. Adherence to treatment with dabigatran etexilate 
Good adherence to treatment is of paramount importance in AF patients under oral 
anticoagulation, either VKA (e.g. warfarin) or NOAC (e.g. dabigatran etexilate). However, 
because of significantly shorter half-life (Table 2) on the contrary to warfarin dabigatran 
etexilate does not offer persistent anticoagulation effect within several days after last dose has 
been taken. Hence, good adherence is even more important in case of treatment with 
dabigatran etexilate. 
 
Discontinuation rates in the RE-LY trial in both dabigatran arms was approximately 20%, but 
rate of discontinuation due to non-adherence was not reported.28  The proportion of patients, 
which were found to have inadequate adherence (assessed as proportion of days covered 
<80%) to treatment with dabigatran etexilate in series of observational studies, ranges 
between 12-39.9%.118-121  In one study, lower adherence was associated with increased risk 
for combined all-cause mortality and stroke (HR 1.13, 95% CI 1.07-1.19 per 10% decrease in 
proportion of days covered).120 
 
There were concerns that non-requirement for regular laboratory monitoring could affect 
adherence. Probably this is not the case since currently available laboratory techniques allow 
us to assess the anticoagulation effect of the last taken dose whilst INR reflects warfarin 
activity across a number of days prior to the measurement. Ре
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Patient education and patient-physician shared decision making with respect to oral 
anticoagulation have tremendous potential to improve patient adherence to treatment, 
whatever anticoagulant is chosen.122-124  
 
5. Conclusion 
 
In terms of efficacy and safety dabigatran is at least non-inferior to warfarin but also has 
important advantages which make dabigatran a favourable option for oral anticoagulation in 
non-valvular AF instead of less convenient warfarin. Data from large randomized clinical 
trials and national registries are proof for this.  
 
Whilst currently available evidence comes from Western countries it is important to get 
insight into patients demography, prescribing patterns of antithrombotic therapy for stroke 
prevention in AF from other countries. Two large, international, observational registries, each 
involving >50 000 patients with newly diagnosed non-valvular AF at risk for stroke from 50 
countries have been designed to investigate patient characteristics influencing choice of 
antithrombotic treatment of stroke prevention in patients with non-valvular AF and to collect 
data on outcomes of antithrombotic therapy in clinical practice: GLORIA-AF (Global 
Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) 
and GARFIELD (Global Anticoagulant Registry in the FIELD).125,126  
 
6. Expert opinion 
 
Oral anticoagulation in AF always requires balancing between risk of stroke and 
thromboembolic complications on the one hand and bleeding event (first of all major and life-Ре
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threatening), on the other. Given poorer outcomes of strokes (higher mortality, disability and 
recurrence rate) if associated with AF, intentions to prevent more strokes at cost of minor 
increase of bleeding seem to be reasonable9,10 - and importantly, consistent with patients’ 
values and preferences.127  
 
Dabigatran etexilate appeared to be at least non-inferior and in several important settings (for 
example reduction of ICH and ischaemic stroke) superior to well-adjusted warfarin therapy as 
assessed in the RE-LY trial. Advantageous pharmacokinetic and pharmacodynamic profile, 
low drug/food interactions of dabigatran etexilate makes anticoagulation effect more stable, 
predictable and understandable. Notwithstanding variability of dabigatran plasma 
concentration with the fixed dose regime, due to wide therapeutic window it did not 
translated into reduction of safety and efficacy of anticoagulation with dabigatran etexilate. 
On the contrary, it is of paramount importance to maintain anticoagulation  within narrow 
therapeutic window of INR 2.0-3.0 when treated with warfarin during ‘good’ time (65-70%), 
which makes anticoagulation safe and effective,128 dabigatran etexilate gives a real alternative 
to patients with non-valvular AF, who experience difficulties with reaching this goal due to 
various reasons. Adjustment of dabigatran etexilate dose based on plasma level has been 
suggested recently that might result in further improvement of outcomes, particularly lower 
bleeding events in patients at higher risk (e.g., elderly, kidney dysfunction, etc.). However, 
this has to be proved with randomised controlled trials and will apparently lead to loss of 
simplicity and practicality of anticoagulation management that is offered by current labelling 
for dabigatran etexilate in comparison to warfarin. Also, this approach cannot be applied 
routinely in the absence of appropriate laboratory assays. 
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In general, patient compliance with dabigatran is less measurable. Whilst INR reflects 
anticoagulation effect of warfarin averaged across a number of days prior to the assessment, 
currently available tests for dabigatran give evidence of last taken dose only. Thus, with 
dabigatran etexilate as well as all other oral anticoagulants, patient education is an important 
means of promoting better adherence to treatment. 
 
Importantly, consistent with the whole RE-LY trial results on dabigatran etexilate safety and 
efficacy were found across various subgroups of patients, e.g., patients with different stroke 
risk according to the CHADS2 score, stage of kidney dysfunction, body mass index, prior 
history of stroke or transient ischaemic attack, presenting with symptomatic heart failure, 
VKA-experienced or naïve, with or without concurrent use of antiplatelets, etc. Only patients 
aged ≥75 years showed higher rate of major bleeding with dabigatran compared to those <75 
years. Nonetheless it remained non-inferior to warfarin.  
 
Of note, majority of bleeding events occurred in the RE-LY trial with dabigatran etexilate 
were those classed as non-major. Notwithstanding the absence of a specific antidote, which is 
currently under testing in an ongoing Phase 3 study (i.e. idarucizumab), activated and non-
activated prothrombin complex concentrate and recombinant factor VII represent effective 
available options to cope with bleeding. 
 
Available evidence from clinical trials and ‘real world’ data already supports use of 
dabigatran etexilate for effective and safe stroke prevention both for chronic anticoagulation 
in AF and range of clinical situations which may appear in everyday practice with two 
exceptions, which are end-stage chronic kidney disease (i.e. CrCl <15 mL/min) and valvular 
AF, broadly defined as AF at a background of prosthetic heart valves or rheumatic heart Ре
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disease (predominantly mitral stenosis). Whilst mechanical prosthetic heart valves were 
found to be absolute contraindication for anticoagulation with  dabigatran etexilate, its use in 
patients with bioprosthetic heart valves is controversial because the latter are likely to be less 
thrombogenic than the artificial surface of the mechanical valves, which induce activation of 
the contact pathway of coagulation. Also, some evidence on efficacy and safety of dabigatran 
etexilate is based on retrospective analyses of subgroups of patients or meta-analyses of 
smaller studies (for example, studies on dabigatran etexilate in patients undergoing catheter 
ablation of AF, which were excluded from the RE-LY trial). Various patients with 
comorbidity (e.g. chronic kidney disease) are less represented in several analyses as well. 
Several ongoing trials were designed and future studies are warranted to cover these gaps.  
 
For now, warfarin will retain its position of the most frequently used oral anticoagulant, 
particularly due to its ‘all-purpose’ applicability, e.g., in patients with valvular AF, end-stage 
kidney dysfunction, prosthetic mechanical valves, etc. Nonetheless, dabigatran etexilate in 
line with the other NOACs has changed the landscape for oral anticoagulation in AF. It 
provides safe and effective stroke prevention in those non-valvular AF patients, who 
experience difficulties with the management of warfarin therapy with respect to maintenance 
of high time in therapeutic range. Clinical decision making tools might aid with the selection 
of appropriate patients for either vitamin K antagonists or NOACs (e.g., dabigatran 
etexilate).129-131 
 
7. Article highlights 
 
 Patients with AF with CHA2DS2-VASc score ≥1 require oral anticoagulation either 
with dose-adjusted warfarin or non-vitamin K antagonist oral anticoagulants (NOAC) Ре
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 Dabigatran, a direct thrombin inhibitor, is free of major warfarin drawbacks as slow 
onset and offset of action, variability of anticoagulant effect, multiple food and drug 
interactions, necessity for regular laboratory monitoring 
 Dabigatran 110 mg bid dosage is non-inferior and 150 mg bid dosage is superior to 
warfarin for prevention of stroke and systemic embolism, whilst 110 mg bid dosage is 
superior and 150 mg bid dosage is non-inferior to warfarin with respect to major bleeding 
events. Both dabigatran dosages are associated with lower risk of intracranial haemorrhage. 
 Dabigatran found to be safe and effective for chronic anticoagulation, cardioversion 
and ablation of atrial fibrillation, in the periprocedural setting, in patients with concomitant 
chronic kidney disease up to end-stage, and in atrial fibrillation at a background of coronary 
heart disease. 
 Ongoing trials on dabigatran will bring further data on its safety and efficacy in areas 
which are currently lacking evidence from randomised control trials and therefore associated 
with some controversy in clinical practice. 
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Table 1. Stroke and bleeding risk stratification with the CHA2DS2-VASc
11 and HAS-
BLED12 scores 
CHA2DS2-VASc Score HAS-BLED Score 
Congestive heart failure/LV 
dysfunction 
1 Hypertension (systolic blood 
pressure >160 mmHg) 
1 
Hypertension 1 Abnormal renal or liver 
function 
1 or 2 
Age ≥75 years 2 Stroke 1 
Diabetes mellitus 1 Bleeding tendency or 
predisposition 
1 
Stroke/TIA/TE 2 Labile INRs (if on warfarin) 1 
Vascular disease (prior MI, 
PAD, or aortic plaque) 
1 Age (e.g., >65, frail condition) 1 
Aged 65–74 years 1 Drugs (e.g., concomitant 
antiplatelet or NSAIDs) or 
alcohol excess/abuse 
1 or 2 
Sex category (i.e. female 
gender) 
1   
Maximum score 9  9 
 
CHA2DS2-VASc: heart failure [moderate-to-severe left ventricular systolic dysfunction refer 
to left ventricular ejection fraction ≤40% or recent decompensated heart failure requiring 
hospitalization], hypertension, age ≥75, diabetes, stroke/transient ischaemic attack [TIA], 
vascular disease [specifically, MI, complex aortic plaque and peripheral artery disease], age 
65–74 years, female sex. Ре
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HAS-BLED: uncontrolled hypertension, abnormal renal/liver function, stroke, bleeding 
history or predisposition, labile international normalized ratio [INR], elderly [e.g. age >65, 
frail condition], drugs [e.g., antiplatelet, non-steroidal anti-inflammatory drugs]/excessive 
alcohol. 
INR, international normalized ratio; LV, left ventricular; MI, myocardial infarction; NSAIDs, 
non-steroidal anti-inflammatory drugs; TIA/TE, transient ischemic attack/thromboembolism; 
PAD, peripheral artery disease. 
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Table 2. Pharmacological characteristics of warfarin and dabigatran16,25-27 
Parameter Warfarin Dabigatran 
Mechanism of action Inhibition of VKORC1 Direct thrombin inhibitor 
(free or bound), reversible 
Onset of action Slow, indirect inhibition of 
clotting factor synthesis 
Fast 
Offset of action Long Short 
Absorption Rapid Rapid, acid-dependent 
Bioavailability, % >95 6.5 
Tmax, hour 2.0-4.0 1.0-3.0 
Vd, L 10 60-70 
Protein binding, % 99 35 
T1/2β, hour 40 12-17 
Renal clearance None 80 
Non-renal clearance None 20 
CL/F, L/hour 0.35 70-140 
Accumulation in plasma Dependent on CYP2C9 
metabolic efficiency 
None 
Food effect No effect on absorption; 
dietary vitamin K influence 
on pharmacodynamics 
Delayed absorption with food 
with no influence on 
bioavailability 
Age Yes, lower CL/F as age 
increases 
Yes, lower CL/F as age 
increases 
Body weight Yes, higher dose for None Ре
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increased weight 
Sex Yes, lower CL/F in women Yes, lower CL/F in women 
Ethnicity Lower dose in Asian patients; 
higher dose in African-
American patients 
None 
Drug transporter None P-gp 
CYP-mediated metabolism CYP2C9, CYP3A4, 
CYP2C19, CYP1A2 
None 
Drug-drug interactions* Numerous Potent P-gp inhibitors 
(verapamil, reduce dose; 
dronedarone: avoid) and 
inducers (avoid) 
Coagulation measurement INR TT, dTT, aPTT, ECA 
Reversal agents Vitamin K (slow reversal, 
prolonged inhibition), FFP or 
PCCs (rapid reversal) 
 
Activated charcoal or 
haemodialysis (overdose); 
PCCs or recombinant FVII 
(uncontrolled bleeding) 
Dosing for AF Individualised for each 
patient according to INR 
response (0.5-16 mg qd) 
150 mg, 110 mg, 75 mg bid† 
AF, atrial fibrillation; aPTT, activated partial thromboplastin test; BCRP, breast cancer 
resistance protein; bid, twice daily; CL/F, apparent clearance; CrCl, creatinine clearance; 
CYP, cytochrom P450 isozymes; dTT, diluted thrombin test; ECT, ecarin chromogenic assay; 
F, factor; FFP, fresh frozen plasma; INR, international normalized ratio; qd, once daily; PCC, 
prothrombin complex concentrate; P-gp, Permeability glycoprotein; PT, prothrombin time; Ре
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Tmax, time to maximum plasma concentration; TT, thrombin time; T1/2β, terminal half-life, Vd, 
volume of distribution; VKORC1, vitamin K epoxide reductase enzyme subunit 1. 
 
* Potent inhibitors of CYP3A4 include antifungals (e.g., ketoconazole, intraconazole, 
voriconazole, posaconazole), chloramphenicol, clarithromycin, and protease inhibitors (e.g., 
ritonavir, atanazavir). P-gp inhibitors include verapamil, amiodarone, quinidine, and 
clarithromycin. P-gp inducers include rifampicin, St. John’s wort (Hypericum perforatum), 
carbamazepine, and phenytoin. Potent CYP3A4 inducers include phenytoin, carbamazepine, 
phenobarbital, and St. John’s wort. 
† 110 mg bid is recommended in Europe for patients aged 80 years or above; concomitantly 
with verapamil; can be considered  in patients aged 75-80 years and high risk of bleeding; in 
patients with gastritis, oesophagitis, or gastroesophageal reflux; in patients with moderate 
renal impairment (CrCl 30-50 mL/min) and high risk of bleeding; contraindicated if CrCl < 
30 mL/min. 75 mg bid is recommended in the US in patients with CrCl 15-30 mL/min 
 
  
Ре
по
зи
то
ри
й Г
рГ
М
У
53 
 
Table 3. Summary on efficacy and safety of dabigatran in pivotal RE-LY trial28,29 and 
‘real world’ Danish Nationwide cohort study39 in patients with non-valvular AF 
Clinical trial RE-LY Danish Nationwide Cohort Study 
Patients  18113 14267 
Age, years  71.8 70.8 
Male gender, % 63.6 56.5 
Median duration of follow-up 2.0 years 10.5 months 
Mean CHADS2 score  2.13 1.16 
Dabigatran dosing arm  110 mg bid 150 mg bid 110 mg bid 150 mg bid 
Prior vitamin K antagonist 
treatment, %  
50.1 50.2 warfarin-naïve patients 
Prior stroke/TIA/systemic 
embolism, % 
20.0 16.1 
Mean TTR, warfarin arm; %  64 NA* 
Stroke/systemic embolism 
0.90 (0.74–
1.10) 
0.65 (0.52-
0.81) 
0.73 (0.53-
1.00) / 0.60 
(0.19-1.60) 
1.18 (0.85-1.64) / 
1.00 (0.26-3.35) 
Death  
0.91 (0.80-
1.03) 
0.88 (0.77-
1.00) 
0.79 (0.65-
0.95) 
0.57 (0.40-0.80) 
Myocardial infarction  
1.29 (0.96-
1.75) 
1.27 (0.94-
1.71) 
0.30 (0.18-
0.49) 
0.40 (0.21-0.70) 
Pulmonary embolism 
1.26 (0.57-
2.78) 
1.61 (0.76-
3.42) 
0.33 (0.12-
0.74) 
0.24 (0.06-0.72) 
Major bleeding  0.80(0.70- 0.93 (0.81- 0.82 (0.59- 0.77 (0.51-1.13) Ре
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0.93) 1.07) 1.12) 
Intracranial hemorrhage  
0.30 (0.19-
0.45) 
0.41 (0.28-
0.60) 
0.24 (0.08-
0.56) 
0.08 (0.01-0.40) 
Gastrointestinal bleeding 
1.09 (0.85-
1.39) 
1.49 (1.19-
1.88) 
0.60 (0.37-
0.93) 
1.12 (0.67-1.83) 
Hospitalisation 
0.92 (0.87-
0.97) 
0.97 (0.92-
1.03) 
0.53 (0.49-
0.57) 
0.86 (0.79-0.93) 
* Mean TTR in Denmark during the RE-LY study was at 72% and has been reported to be 
>65% in both hospitals and in general practice 
NA, not available 
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Table 4. Summary of meta-analyses on dabigatran safety and efficacy in patients with 
non-valvular AF undergoing catheter ablation 
References Number 
of 
studies 
included  
Number of 
participants 
involved* 
Thrombo-
embolic 
event rate, 
%* 
Risk of 
thromboembolic 
complications, 
OR, 95% CI 
Major 
bleeding 
rate, %* 
Risk of major 
bleeding, OR, 
95% CI 
Bin Abdulhak et 
al68 
9 1073/1963 0.4/0.1 2.15 (0.58-7.98) 5.4/5.2† 0.92 (0.55-1.45) 
Hohnloser et al69 10 1407/2241 0.64/0.13 2.38 (0.82-6.85) 1.71/1.56 1.05 (0.62-1.80) 
Providência et al70  14 1823/2959 0.55/0.17 1.78 (0.66-4.80) 1.48/1.35 1.07 (0.51-2.26) 
Sardar et al71 18 2137/3376 0.74/0.21 2.81 (1.23-6.45) 1.54/1.57 0.99 (0.55-1.78) 
Shurrab et al72 11 1463/2378 0.6/0.1 2.51 (0.78-8.11) 1.9/1.6 1.04 (0.51-2.13) 
Steinberg et al73 10 1501 /2356 0.7/0.2 0.0047 (0.0007-
0.0099)‡ 
1.6/1.7 −0.0010 (−0.0090-
0.0076) ‡ 
* dabigatran/warfarin 
† total bleeding 
‡ estimated absolute risk difference 
OR, odds ratio; CI, confidence interval 
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Figure 1. Coagulation cascade and application points for dabigatran and warfarin132 
Solid line, affects synthesis in direct way; dashed line, affects activation via thrombin inhibition; F, factor; Pt, platelet; TF, tissue factor
Platelet 
activation 
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